Closed-Loop Insulin Pumps Show Promise for Pregnant People with Type 1 Diabetes

Pregnancy with Type 1 diabetes carries real risks. About half of pregnant people with Type 1 diabetes experience hyperglycemia-related complications—meaning their blood sugar stays too high despite their best efforts. High blood sugar during pregnancy increases the risk of serious problems for both mother and baby.

Managing Type 1 diabetes during pregnancy is harder than at other times. Pregnancy-specific blood sugar targets are narrower (63–140 mg/dL), and the stakes feel higher. Pregnant people need support from both insulin and emerging technology to hit these tighter goals.

A randomized clinical trial published in JAMA tested closed-loop insulin systems in 91 pregnant women with Type 1 diabetes across Canada and Australia. Closed-loop systems use a glucose sensor and an insulin pump that 'talk' to each other—the pump automatically adjusts insulin delivery based on real-time blood sugar readings, with minimal input from the user.

From weeks 16 to 34 of pregnancy, women using closed-loop systems spent an average of 65.4% of the time in the pregnancy-specific glucose range. Women using standard care (insulin pumps or multiple daily injections with continuous glucose monitoring) spent 50.3% of the time in range. That 15-percentage-point difference matters: more time in target range means lower risk of hyperglycemia-related complications.

The trial also tracked safety. There was one episode of severe low blood sugar in the closed-loop group and two episodes of diabetic ketoacidosis in that group, compared to one episode of ketoacidosis in the standard care group. These are important safety considerations, though the trial was relatively small.

Closed-loop systems represent a meaningful step forward in diabetes management. A small glucose sensor under the skin checks blood sugar continuously. That data feeds into an insulin pump programmed with an algorithm—essentially a set of automatic rules about how much insulin to give based on current glucose levels.

The advantage: instead of deciding every few hours whether to take insulin, the system makes those decisions in real time, reducing both the cognitive load and the guesswork. Research shows that diabetes technologies overall—including continuous glucose monitors, automated insulin delivery systems, and connected insulin pens—have improved glycemic control, patient satisfaction, and quality of life for people with Type 1 diabetes.

Closed-loop systems are powerful tools, but they're not a standalone solution. Clinical guidelines from the Endocrine Society and European Society of Endocrinology emphasize that reducing pregnancy complications requires preconception care—achieving good blood sugar control before you become pregnant. Only a minority of people with Type 1 diabetes currently receive this kind of planned preconception support.

Pregnancy planning also includes nutrition counseling, management of insulin-sensitizing medications, and attention to obesity, which affects pregnancy outcomes independently of blood sugar control. Mental health matters too: depression and anxiety affect about 40% of adolescents with Type 1 diabetes and can undermine treatment adherence.

For anyone with Type 1 diabetes considering pregnancy, the evidence suggests that working with an endocrinologist and diabetes care team months before conception—to optimize your A1c, discuss technology options, and address nutrition and mental health—offers the best chance of a healthy pregnancy.

Origin: YouTube / Juicebox Podcast (Video report). Evidence: Video report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.